SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE).   The class action, filed in the United States District Court for the Southern District of California, and docketed under 23-cv-111-WQH-NLS, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fate securities between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased or otherwise acquired Fate securities during the Class Period, you have until March 22, 2023 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Fate is a clinical-stage biopharmaceutical company that develops programmed cellular immunotherapies to treat cancer and immune disorders.

On April 2, 2020, after the market closed, Fate announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment (the “Janssen Collaboration Agreement”). In addition, Fate was eligible for up to $3 billion in various milestone payments and double-digit royalties on any net sales from the collaboration. On the news, Fate’s stock price jumped 8.8% in trading on April 3, 2020.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Janssen Collaboration Agreement was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement’s on Fate’s long-term clinical and commercial profitability; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On January 5, 2023, after the markets closed, Fate issued a press release announcing that it had terminated the Janssen Collaboration Agreement. Specifically, the Company disclosed that it was “not able to align with Janssen on their proposal for continuation of our collaboration, where two product candidates targeting high-value, clinically-validated hematology antigens were set to enter clinical development in 2023[.]” As a result of the termination, Fate revealed that all licenses and other rights granted pursuant to the Janssen Collaboration Agreement would terminate, that it would reduce its headcount to about 220 employees in Q1 2023, and that it would discontinue several of its natural cell killer programs in various cancers, including FT516 and FT538 NK cell programs in acute myeloid leukemia, FT516 and FT596 NK cell programs in B-cell lymphoma, and FT538 and FT536 NK cell programs in solid tumors.

On this news, Fate’s stock price fell $6.76 per share, or 61.45%, to close at $4.24 per share on January 6, 2023.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:

Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980



SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

TIN LIÊN QUAN

Notice of Filing Securities Class Action Against Global

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. has filed a federal securities class action in the United States District Court...

CRBU Class Action Lawsuit Announced: Johnson Fistel

SAN DIEGO, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on...

BROS EQUITY ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM,

NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on...

Vertex Energy, Inc. (VTNR) Shareholder Notice: Robbins LLP

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons...

Caribou Biosciences, Inc. (CRBU) Shareholder Alert: Robbins

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or...

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Atlassian

NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Atlassian...

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kornit Digital

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kornit...

SUNL FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL,

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sunlight...

THỦ THUẬT HAY

Mật khẩu của bạn thực sự đã mạnh ?

Mật khẩu là hàng phòng thủ đầu tiên chống lại tội phạm mạng. Điều cốt yếu là phải chọn các mật khẩu khác nhau đủ mạnh cho từng tài khoản quan trọng và bạn nên cập nhật mật khẩu thường xuyên. Hãy thực hiện theo những mẹo

Kích hoạt chế độ quay video [email protected] cho Galaxy Note 8/S8/S8+ với vi xử lý Exynos

Cụ thể hơn, ngay từ thế hệ vi xử lý Exynos 8895 ra mắt năm 2017, khả năng quay video [email protected] đã được hỗ trợ trong khi phiên bản cùng đẳng cấp là Snapdragon 835 vẫn chưa thể đáp ứng khả năng này. Vấn đề đặt ra

Cách viết ghi chú mũi tên trong Word

Trong Words, khi biểu diễn một đoạn văn bản cần sơ đồ, hình khối có lẽ biểu tượng mũi tên sẽ được người dùng sử dụng nhiều nhất. Đặc biệt viết chú thích lên mũi tên sẽ làm tăng thêm tính trực quan của biểu đồ mà bạn

Google thêm tính năng chia sẻ lịch sử vào Chrome cho iOS

Các tùy chọn mới bao gồm chia sẻ các trang web với các mạng xã hội và thông qua tin nhắn. Các ứng dụng Android cũng sẽ có các tính năng tương tự.

12 bài tập để có đôi chân chắc khỏe dành cho mọi lứa tuổi

Những bài tập chân đơn giản, không cần dụng cụ và ai cũng có thể tập.

ĐÁNH GIÁ NHANH

Đánh giá HP ProBook 450 G3: Đâu phải cứ "doanh nhân" là đắt tiền

Thiết kế bền bỉ với tiêu chuẩn quân đội, màn hình lớn kết hợp với nhiều công nghệ bảo mật, HP ProBook 450 G3 xứng đáng là một chiếc laptop doanh nhân cao cấp.

Oppo tung ra Find X6 Pro với cảm biến 1-inch và camera periscopic

Oppo Find X6 Pro được trang bị cảm biến 1-inch, lớn hơn so với hầu hết các cảm biến điện thoại thông minh trên thị trường hiện nay. Điều này có nghĩa là camera có khả năng thu được nhiều ánh sáng hơn, dẫn đến chất lượng

Đánh giá hiệu năng Asus GL553VD - Mạnh mẽ với Intel Core i7 KabyLake và GTX 1050

Asus GL553VD mang trên mình một thiết kế mới và bên trong nó là một cấu hình mạnh mẽ từ CPU Intel KabyLake cùng GPU GeForce 1050 mới nhất thời điểm hiện tại. Hãy cùng FPTshop đánh giá hiệu năng thực tế của sản phẩm...